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VEGF-C/VEGFR-3 signaling plays a central role in
lymphatic development, regulating the budding
of lymphatic progenitor cells from embryonic veins
and maintaining the expression of PROX1 during
later developmental stages. However, how
VEGFR-3 activation translates into target gene
expression is still not completely understood. We
used cap analysis of gene expression (CAGE)
RNA sequencing to characterize the transcriptional
changes invoked by VEGF-C in LECs and to
identify the transcription factors (TFs) involved. We
found that MAFB, a TF involved in differentiation
of various cell types, is rapidly induced and acti-
vated by VEGF-C. MAFB induced expression of
PROX1 as well as other TFs and markers of dif-
ferentiated LECs, indicating a role in the mainte-
nance of the mature LEC phenotype. Correspond-
ingly, E14.5 Mafb/ embryos showed impaired
lymphatic patterning in the skin. This suggests
that MAFB is an important TF involved in lymphan-
giogenesis.
INTRODUCTION
The development of the lymphatic system in mice begins
around embryonic day (E) 9.5, when a subpopulation of venous
endothelial cells starts expressing the transcription factor (TF)
prospero homeobox 1 (PROX1) and forms patches of lymphatic
endothelial cell (LEC) progenitors (reviewed in Koltowska et al.,Cell Rep2013 and Yang and Oliver, 2014). Around E10.5–E11.5, LEC
progenitor cells bud off the veins and form primary lymphatic
structures (Franc¸ois et al., 2012; Ha¨gerling et al., 2013; Yang
et al., 2012). During this stage, migrating cells upregulate podo-
planin (PDPN), a marker of differentiated LECs that is absent
from the PROX1+ LEC progenitors in the veins (Franc¸ois
et al., 2012; Yang et al., 2012). Continuous sprouting and
migration of LECs during the following days give rise to a prim-
itive lymphatic plexus that undergoes further maturation to form
initial and collecting lymphatic vessels. At E14.5, the subcu-
taneous lymphatic network is forming, with lymphatic vessels
growing dorsolaterally from the sides toward the dorsal midline.
Finally, formation of lymphatic valves in collecting vessels be-
gins around E16.0 and indicates complete differentiation of
these vessels (Sabine et al., 2012). Of note, a recent report
has also suggested a non-venous origin of lymphatic vessels
in the lumbar region of the back skin (Martinez-Corral et al.,
2015).
Several TFs play a crucial role in the coordination of
lymphatic development. PROX1 is a key TF for LEC differenti-
ation. Prox1/ embryos fail to develop any lymphatic vessels
because LEC fate specification in the embryonic veins is
impaired (Wigle and Oliver, 1999). Even in Prox1 heterozygous
mice, the number of LEC progenitors is reduced severely (Har-
vey et al., 2005; Srinivasan and Oliver, 2011), indicating that the
expression level of PROX1 needs tight regulation for normal
lymphangiogenesis. Two TFs, sex-determining region Y box
18 (SOX18) and nuclear receptor subfamily 2, group F, mem-
ber 2 (NR2F2, also called COUP-TFII) have been shown to be
required for the initial induction of PROX1 expression (Franc¸ois
et al., 2008; Srinivasan et al., 2010). Furthermore, COUP-TFII is
needed for maintenance of PROX1 expression during LEC
specification but not in fully differentiated LECs (Johnsonorts 13, 1493–1504, November 17, 2015 ª2015 The Authors 1493
Figure 1. RNA Sequencing of Primary
Human LECs
(A) Diagram of the CAGE RNA sequencing
approach. Primary human LECs from three indi-
vidual donors were stimulated with VEGF-C156S,
and RNA was extracted and subjected to
sequencing at 16 different time points over a
period of 0–480 min.
(B) Diagram of the ten most significantly enriched
GO terms (molecular function) associated with all
upregulated genes.
(C) Graph representing the number of upregulated
TFs in comparison with all upregulated genes for
each time point.
See also Figure S1 and Table S1.et al., 2008; Lin et al., 2010; Srinivasan et al., 2010). Another
important molecular cue for lymphatic development is signal
transduction through the vascular endothelial growth factor C
(VEGF-C)/VEGF receptor 3 (VEGFR-3) axis. During embryonic
development, VEGFR-3, encoded by the Flt4 gene, is ex-
pressed by venous endothelial cells but is upregulated in LEC
precursors (Kukk et al., 1996). Its ligand VEGF-C is expressed
in the mesenchyme, and VEGF-C/VEGFR-3 signaling is
crucial for budding and guidance of primitive LECs (Karkkainen
et al., 2004). In addition, VEGF-C/VEGFR-3, together with the
VEGF-C co-receptor neuropilin 2 (NRP2), is needed for
lymphatic vessel sprouting and lymphangiogenesis during later
stages of development and for postnatal lymphangiogenesis
(Rutkowski et al., 2013; Xu et al., 2010; Yuan et al., 2002).
A recent report has demonstrated that a positive feedback
loop between PROX1 and VEGFR-3 expression is also required
for the maintenance of the LEC phenotype during later stages
of development (Srinivasan et al., 2014). In this study, the au-
thors showed that PROX1 is a direct regulator of VEGFR-3
expression and that VEGFR-3 is needed to maintain PROX1
expression, although the precise molecular pathway linking
VEGFR-3 and PROX1 induction remains unknown.
Binding of VEGF-C to VEGFR-3 is well known to result in
rapid phosphorylation of several tyrosine residues in the cyto-
plasmic tails of VEGFR-3, activating downstream signaling cas-
cades, including the phosphatidylinositol 3-kinase (PI3K) and
Raf-MEK-ERK pathways (reviewed in Koch et al., 2011). How-
ever, despite the importance of this signaling axis for the devel-
opment and maintenance of the lymphatic system, it is still not
understood how these signals are translated into a transcrip-
tional response in LECs and which TFs are involved. Here we
characterized the immediate transcriptional changes down-
stream of VEGFR-3 activation in LECs in detail using cap
analysis of gene expression (CAGE) RNA sequencing (Kana-
mori-Katayama et al., 2011; Shiraki et al., 2003) in conjunction
with the FANTOM5 project (http://fantom.gsc.riken.jp/5/). Of1494 Cell Reports 13, 1493–1504, November 17, 2015 ª2015 The Authorsnote, we found upregulation of multiple
TFs, including the well known regulators
of PROX1 expression, SOX18 and krup-
pel-like factor 4 (KLF4) (Franc¸ois et al.,
2008; Park et al., 2014). Importantly, we
identified MAFB as a lymphatic TF acti-vated by VEGF-C and suggest that MAFB regulates lymphan-
giogenesis by upregulation of PROX1.
The work presented here is part of the FANTOM5 project
(Arner et al., 2015; Forrest et al., 2014). Data downloads,
genomic tools, and co-published manuscripts have been sum-
marized at http://fantom.gsc.riken.jp/5/.
RESULTS
Activation of VEGFR-3 Induces Expression of Multiple
Transcription Factors
To investigate acute transcriptional changes in response to
VEGFR-3 stimulation, we treated primary LECs derived from
three individual donors with the VEGFR-3-specific ligand
VEGF-C156S (Joukov et al., 1998), isolated RNA at 16 different
time points from 0–480 min, and subjected it to CAGE RNA
sequencing (Figure 1A). In total, we found 241 genes upregulated
at at least one of the time points (Table S1). Gene ontology (GO)
analysis showed that a large number of those genes were either
TFs or otherwise related to transcriptional regulation. In fact, 7 of
the 10 most significantly enriched GO molecular function terms
were related to the regulation of gene expression (Figure 1B). In-
duction of TFs was particularly strong during the early time
points after stimulation, from 15–210 min (Figure 1C), indicating
that a wave of immediately induced TFs controls downstream ef-
fects of VEGFR-3 stimulation in LECs.
VEGFR-3 Stimulation Specifically Induces Expression of
MAFB, KLF4, and SOX18 in LECs
In total, we found 50 TFs among the VEGF-C156S-induced
genes (Figure 1C; Table S1). Using qPCR, we could validate
upregulation of 17 of these TFs during the early phase of the
stimulation (expression peak between 30 and 80 min after stim-
ulation) (Figure 2B; Figures S1A–S1P). Many of these 17 TFs,
such as EGRs, FOS, JUN, etc., are considered ‘‘immediate early
genes’’ (IEGs) that are well known to be upregulated in various
Figure 2. MAFB Is Upregulated and Active in
VEGF-C156S-Stimulated LECs
(A) Normalized upregulation of MAFB transcripts
(tags per million [TPM]) according to CAGE RNA
sequencing (RNA-seq). Data points represent the
mean ± SD of LECs from three individual donors.
(B) Validation of MAFB upregulation by qPCR
(one representative donor). Error bars represent
mean + SD.
(C) Western blot showing transient upregulation of
MAFB protein.
(D) Activity plots showing significant enrichment of
predicted MAFB_1 binding sites in promoters of
differentially expressed (Z-score higher than the
mean + 1.5 3 SD, indicated by a horizontal line) at
the time points of 45, 60, 210, and 360 min. Each
plot provides the Z-score of the TF binding profiles
on the y axis, whereas the x axis represents the
percent guanine and cytosine (%GC) content of
the profiles.
See also Figure S2 and Table S2.cell types by awide variety of stimuli. To identify TFs that are spe-
cifically induced by VEGFR-3 stimulation in LECs, we compared
our data to the results of published gene set enrichment analyses
(GSEAs) on other stimulation experiments (VEGF-A-treated hu-
man umbilical vein endothelial cells (HUVECs) and epidermal
growth factor [EGF]-treated MCF7, MCF10A, and HeLa cells;
Abe and Sato, 2001; Amit et al., 2007; Nagashima et al., 2007).
As expected, the majority of TFs were upregulated in one or
several of the comparison datasets, meaning that they represent
IEGs. Upregulation of only three TFs,MAFB (V-maf musculoapo-
neurotic fibrosarcoma oncogene homolog B),KLF4, and SOX18,
was induced selectively in VEGF-C156S-stimulated LECs.
MAFB regulates the differentiation of multiple cell types,
including monocytes/macrophages, kidney podocytes, and
pancreatic a and b cells (Friedman, 2007; Hang and Stein,
2011; Yang and Cvekl, 2007). In contrast to KLF4 and SOX18,
a role of MAFB in LECs has not been described before. In our da-
taset,MAFB was induced rapidly in LECs and reached maximalCell Reports 13, 1493–1504, Noexpression during the first 2 hr after
VEGFR-3 stimulation (Figures 2A and
2B). This induction was reflected by an in-
crease in MAFB protein, which slowly
accumulated during the first 3–4 hr after
stimulation and dropped back toward
the baseline at later time points
(Figure 2C).
MAFB Actively Regulates Gene
Expression in Response to VEGFR-3
Stimulation
Next we aimed to investigate whether
MAFB is involved in the regulation of
target genes in LECs in response to
VEGFR-3 stimulation. Using the CAGE
RNA sequencing data, we identified the
transcriptional start sites (TSSs) of all up-
regulated genes in our dataset, extractedthe core promoter sequence around them (1,500 to +500 base
pairs [bp]), and searched for MAFB binding sites using
oPOSSUM-3 (Kwon et al., 2012). MAFB is known to bind
MAFB response elements (MAREs) with the consensus
sequence TGCTGAC, and to ‘‘degenerated’’ MAREs with the
consensus sequence TGCNNNN (Eyche`ne et al., 2008). Accord-
ingly, analyses of protein binding microarray data have identified
two distinct types of TF binding profiles for MAFB (Badis et al.,
2009). These TF binding profiles are denoted as ‘‘MAFB_1’’
and ‘‘MAFB_2’’ in the publically available TF binding site data-
base JASPAR (Mathelier et al., 2014; Figure S2A). Using
oPOSSUM-3, we found a significant enrichment of MAREs in
the core promoters of upregulated genes after 45, 60, 210, and
360 min (Figure 2D; Table S2). Similarly, we also found a signifi-
cant enrichment for the number of genes with at least one
MAFB_1 or MAFB_2 element in the core promoter among all up-
regulated genes after 15, 210, and 360min (Figure S2B). This is a
strong indication that MAFB is indeed active after VEGFR-3vember 17, 2015 ª2015 The Authors 1495
Figure 3. MAFB Is Selectively Expressed in LECs Compared with BECs
(A) qPCR showing relative expression of MAFB in cultured human LECs and BECs of the same donor. Error bars represent mean + SD of three independent
experiments.
(B) Western Blot for MAFB protein in cultured human LECs and BECs of three individual donors.
(C) Gating strategy used for FACS of LECs and BECs from mouse back skin (plots pre-gated for live, single cells). CD45CD31+Podoplanin+ cells were
considered as LECs and CD45CD31+Podoplanin cells as BECs.
(D) qPCR showing MAFB expression in LECs and BECs sorted by FACS from mouse back skin. Error bars represent mean + SD (n = 5–6).
(E and F) Representative qPCR ofMAFB expression in LECs (E) and BECs (F) treated with VEGF-A, EGF, FGF-2, and HGF at the indicated doses for 1 or 6 hr. One
representative of two independent experiments is shown. See also Figure S3. Error bars represent mean + SD.
(G) qPCR of MAFB expression in LECs after siRNA knockdown of PROX1. Error bars represent mean + SD of four independent experiments (*p < 0.05).stimulation and induces further target genes, mediating at least a
part of the downstream effects.
MAFB Is Selectively Expressed and Inducible in LECs
Compared with BECs
Having established the specific induction and activity ofMAFB in
VEGF-C156S-stimulated LECs, we next investigated the expres-
sion pattern ofMAFB in the endothelium in greater detail. In line
with previous reports (Hirakawa et al., 2003; Petrova et al.,
2002), we found that MAFB expression was detectable in both
cultured human LECs and blood vascular endothelial cells1496 Cell Reports 13, 1493–1504, November 17, 2015 ª2015 The Au(BECs) and was increased markedly in LECs both at the mRNA
and the protein level (Figures 3A and 3B). Similarly, we found
thatMAFB expression was higher in LECs than in BECs isolated
from mouse back skin by fluorescence-activated cell sorting
(FACS) (Figures 3C and 3D).
We next tested the effect of other growth factors that have
been implied in lymphangiogenesis on the MAFB expression
level in LECs and BECs.MAFB expression in LECs was induced
by VEGF-A and HGF after 1 hr and returned to baseline levels
after 6 hr (Figure 3E). The effect of VEGF-A was comparable
with that of VEGF-C and VEGF-C156S (Figure S3A). In contrast,thors
Figure 4. MAFB Is Present in Lymphatic
Vessels in the Mouse
Maximum-intensity projections of confocal images
of mouse (C57BL/6 wild-type) tissue whole mounts
stained for CD31 (green), PROX1 (red), and MAFB
(blue).
(A) Postnatal diaphragm (P2).
(B) Foot skin (adult).
(C) Ear skin (adult). Arrows indicate colocalization
of MAFB and PROX1. LV, lymphatic vessel; BV,
blood vessel.
(D) Maximum intensity projection and 3D recon-
struction with orthogonal views of a lymphatic
vessel in the ear skin. Colocalization of PROX1 and
MAFB in the z direction is indicated by arrows.
See also Figure S4.no effect onMAFB expression was seen in BECs (Figure 3F; Fig-
ure S3B). This is in line with the GSEA that indicated thatMAFB is
not induced in VEGF-A-treated HUVECs (Abe and Sato, 2001).
PROX1 is considered a fate-determining transcription factor
for LECs, regulating the expression of many genes involved in
LEC differentiation (Koltowska et al., 2013; Yang and Oliver,
2014). To investigate whether PROX1 might be responsible for
the preferential expression of MAFB in LECs, we used small
interfering RNA (siRNA) to deplete PROX1 expression. Knock-
down of PROX1 in cultured LECs with two individual siRNAs
was associated with decreased MAFB expression (Figure 3G;
Figure S3C), indicating that MAFB is a PROX1 target gene.
MAFB Is Expressed in Lymphatic Vessels In Vivo
To further investigate the expression ofMAFB in lymphatic endo-
thelium in vivo, we stained tissue whole mounts with a MAFB-
specific antibody in combination with antibodies to the lymphatic
marker PROX1 and the pan-vascular marker CD31. MAFB stain-
ing was detected in the developing lymphatic vessels in the
diaphragm (P2) as well as in the foot and ear skin of adult mice
(Figures 4A–4C). Lymphatic MAFB staining was nuclear and
completely overlappedwithPROX1staining (Figure 4D), confirm-Cell Reports 13, 1493–1504, Noing that MAFB is indeed expressed by
lymphatic endothelial cells in vivo. MAFB
staining was not detected in CD31+
PROX1 blood vessels (Figures 4A–4C).
Strong MAFB expression was also found
in non-vascular single cells in all tissues
analyzed. Co-staining for CD68, CD206,
and LYVE-1 revealed that virtually all of
these cells were macrophages (Figures
S4A and S4B), in agreement with previous
studies (Sieweke et al., 1996).
MAFB Regulates the Expression of
Several Key Transcription Factors
and Differentiation Markers in LECs
To investigate whether MAFB expression
might affect the LEC phenotype, we over-
expressed MAFB in cultured LECs using
adenovirus (Ad-MAFB). Cells infectedwith a GFP virus (Ad-GFP) served as a control. We achieved
high MAFB expression both at the RNA and protein level for at
least 72 hr after infection (Figures S5A and S5B). CAGE RNA
sequencing of LECs 24 hr after adenovirus infection showed
that MAFB overexpression resulted in significant (log2 fold
change [log2FC] > 1, false discovery rate [FDR] < 5%) upregula-
tion of a large set of target genes (Table S3). Among the upregu-
lated genes were LYVE1 and PDPN, two major markers of
lymphatic differentiation. We therefore investigated the expres-
sion of additional key LEC markers at several time points (24,
48, and 72 hr) after adenovirus infection by qPCR. We found a
strong upregulation of PROX1 mRNA 72 hr after MAFB overex-
pression (Figure 5A). In line with this, the protein level of
PROX1 was also higher than in control cells at this time point.
There was a steady decrease of PROX1 expression in control
LECs over time that was not seen in MAFB-overexpressing
LECs (Figures 5B and 5C). We also found upregulation of KLF4
after 48 and 72 hr and of NR2F2 (COUP-TFII) after 72 hr (Figures
5D and 5E). Surprisingly, expression of SOX18 was initially
decreased but later increased, which may be due to MAFB
acting as transcriptional activator or repressor, depending on
the context (Figure 5F). Additionally, we found a strong inductionvember 17, 2015 ª2015 The Authors 1497
Figure 5. Overexpression of MAFB Upregulates Key Transcription Factors and Differentiation Markers in LECs
(A) Upregulation of PROX1mRNA inMAFB-overexpressing cells (gray bars) compared with control cells (black bars), determined by qPCR. One representative of
three independent experiments is shown. Error bars represent mean + SD.
(B and C) Western Blot (B) and densitometric measurement of signal intensity (C) to determine PROX1 protein in MAFB-overexpressing LECs.
(D–J) qPCR data showing expression of KLF4 (D), NR2F2 (COUP-TFII) (E), SOX18 (F), LYVE1 (G), PDPN (H), FLT4 (VEGFR-3) (I), and CCL20 (J) in LECs over-
expressing MAFB compared with control cells. One representative of three independent experiments is shown. Error bars represent mean + SD.
See also Figure S5 and Table S3.of LYVE1, PDPN, and FLT4 (VEGFR-3) at one ormore time points
after infection (Figures 5G–5I). An unrelated control gene,
CCL20, was not affected by MAFB overexpression (Figure 5J).
Taken together, these data suggest that MAFB contributes to
the regulation of the LEC phenotype by modulating the expres-
sion ofmultiple key TFs andmarker genes of differentiated LECs.1498 Cell Reports 13, 1493–1504, November 17, 2015 ª2015 The AuMAFB Binds to Regulatory Elements in the Genes of Key
LEC TFs
The effect of MAFB on the expression of LEC-associated TFs
could have been direct through binding of MAFB to regulatory
elements of the corresponding genes or indirect via induction
of intermediate mediator genes. We next searched for potentialthors
Figure 6. MAFB Binds to Regulatory Ele-
ments in the PROX1, KLF4, NR2F2AS1, and
SOX18 Genes
(A) Sequences of ChIP-validated MAFF/MAFK
binding areas according to ENCODE. Boxes indi-
cate the most likely MAFB binding site as deter-
mined by JASPAR.
(B) qPCR showing enrichment of all four DNA areas
shown in (A) in MAFB-immunoprecipitated chro-
matin compared with mock-immunoprecipitated
chromatin from MAFB-overexpressing cells.
Enrichment of the binding site in the KLF4 gene
could also be detected in control cells. A DNA
stretch without MAFB bindings sites (CCL4) served
as a negative control. One representative of three
independent experiments is shown. Error bars
represent mean + SD.MAREs in the promoters and the coding regions of PROX1,
KLF4, NR2F2, and SOX18. Recently, the Encyclopedia of
DNA Elements (ENCODE) project published chromosome
immunoprecipitation (ChIP) data for multiple transcription fac-
tors (ENCODE Project Consortium, 2011; Wang et al., 2012).
Although MAFB itself was not investigated, the closely related
MAFF and MAFK, which can bind to identical DNA sequences,
are included. ChIP-validated MAFF/MAFK binding sites are
present in the first intron of PROX1, the promoter region of
KLF4, and the second exon of SOX18. No binding site was
found within or in close proximity to the NR2F2 gene. However,
there is a MAFF binding site about 60 kb upstream of the TSS,
in a region coding for an NR2F2 antisense RNA (NR2F2AS1).
MAFB binding to this site might regulate expression of
NR2F2 directly or indirectly through regulation of NR2F2AS1.
We designed primers for the corresponding DNA elements
(Figure 6A) and performed ChIP with a MAFB-specific anti-
body, followed by qPCR on LECs 72 hr after infection withCell Reports 13, 1493–1504, NoAd-MAFB (at the same time point when
PROX1 expression was induced). Ad-
GFP-infected cells as well as mock
immunoprecipitation (IP) with a nonspe-
cific antibody served as controls. There
was a clear ChIP signal for all four puta-
tive binding sites in MAFB-overexpress-
ing cells, whereas a locus without a
predicted MAFB binding site (CCL4)
was not enriched (Figure 6B). We also
repeatedly detected a slight enrichment
of the suggested binding site in the
KLF4 promoter in control cells (1.3-to
2.2-fold over mock IP), indicating that
this binding site is occupied by MAFB
protein even in unstimulated, resting
LECs. Although these findings do not
preclude any indirect regulation of
PROX1, KLF4, or SOX18 by MAFB,
they strongly suggest that MAFB regu-
lates their expression by directly binding
to cis-regulatory elements of the corre-sponding genes and that MAFB might regulate expression of
NR2F2 indirectly through NR2F2AS1.
MAFB Controls Lymphatic Patterning during
Embryogenesis
We next investigated whether MAFB might also play a role in
lymphatic vessel development in vivo. We studied lymphatic
vessels in the embryonic back skin at E14.5, a time point
when lateral lymphatic vessels are growing toward the dorsal
midline in a highly stereotypical manner, in Mafb/ mice and
wild-type (WT) littermates. Using back skin whole mounts
stained for NRP2 and PROX1 to identify lymphatic vessels (Fig-
ure 7A), we observed a slight trend toward an increased
distance from the lymphatic vessel tips to the midline in
Mafb/ mice compared with WT littermates, indicating that
lymphangiogenesis may be retarded (Figure 7B). There were
also significant aberrations in the lymphatic patterning in the
skin of Mafb/ mice, with an increased number of vesselvember 17, 2015 ª2015 The Authors 1499
Figure 7. Lymphatic Patterning Is Impaired
during Embryogenesis in Mafb/ Mice
(A) Representative confocal images (maximum-
intensity projections) of E14.5 embryonic back skin
stained for NRP2 (green) and PROX1 (red). Dashed
lines indicate the midline. Dashed boxes indicate
the distal sprouting area, defined as a 500-mm-
wide area from the lymphatic vessel tips toward
the sides. Arrowheads point to vessel junctions
(branch points) within the distal sprouting area.
(B) Average distance to the midline in wild-type
(n = 10) and Mafb/ (n = 7) embryos. n.s., not
significant.
(C) Number of vessel junctions normalized to total
vessel length in the distal sprouting area of wild-
type (n = 10) and Mafb/ (n = 7) embryos
(*p < 0.05).
(D) Proposed model of MAFB involvement in the
regulation of lymphangiogenesis. MAFB regulates
PROX1 expression both directly and indirectly
through KLF4, SOX18, and COUP-TFII upregula-
tion, the latter possibly through the antisense RNA
NR2F2AS1. PROX1, in turn, maintains MAFB
expression in differentiated LECs.
See also Figure S6.junctions and vessel segments, and a correspondingly
decreased average segment length (Figure 7C; Figures S6D
and S6E) measured in the ‘‘distal sprouting area,’’ defined as
the area spanning 500 mm from the lymphatic tips toward the
sides (Figure 7A). There were no major differences in total
lymphatic vessel length, vessel area, or number of PROX1+
cells (Figures S6A–S6C). No differences in the lymphatic ves-
sels were found in the ‘‘proximal network area,’’ defined as
the area beginning 100 mm laterally from the distal sprouting
area (Figures S6F–S6K). Taken together, these data show
that MAFB is not absolutely required for lymphangiogenesis
but involved in the fine patterning of growing lymphatic vessel
tips in the embryonic back skin. Mafb/ mice have a complex
phenotype because MAFB is expressed in multiple cell types
and tissues, including tissue macrophages, which might modu-
late lymphangiogenesis. However, we found that the number of
LYVE-1+ macrophages was not changed in the back skin of
Mafb/ embryos (Figures S6L and S6M), in line with previous
reports that macrophages in Mafb/ mice only display slight
phenotypic changes compared with WT mice (Aziz et al.,
2006; Moriguchi et al., 2006), indicating that MAFB regulates
lymphatic patterning most likely in a cell-autonomous fashion.1500 Cell Reports 13, 1493–1504, November 17, 2015 ª2015 The AuthorsDISCUSSION
VEGFR-3 signaling plays a central role in
lymphatic biology, both in the develop-
ment of the lymphatic network during
embryogenesis as well as in postembry-
onic lymphangiogenesis and the regula-
tion of lymphatic function (reviewed in
Koltowska et al., 2013; Yang and Oliver,
2014). Although the immediate signaling
events downstream of receptor stimula-tion leading to activation of the MAPK and PI3K pathways
have been investigated in great detail (Koch et al., 2011), little
is known about how these signals are translated into a transcrip-
tional response (Shin et al., 2008). Here, we comprehensively
characterized immediate gene expression changes in LECs after
VEGFR-3 stimulation using CAGE RNA sequencing in conjunc-
tion with the FANTOM5 project (http://fantom.gsc.riken.jp/5/).
Because VEGF-C, the principal ligand of VEGFR-3, has been
reported to bind to and activate VEGFR-2 (Joukov et al., 1997),
we used VEGF-C156S, a mutated form of VEGF-C selectively
binding to VEGFR-3 but not VEGFR-2 (Joukov et al., 1998),
and followed changes in gene expression over a period of 8 hr
by CAGE RNA sequencing. This analysis revealed that, of
the genes upregulated by VEGF-C156S, a significant portion
were TFs.
Many of these TFs are well known immediate-early TFs that
are induced non-selectively by MAPK signaling in many cell
types. However, when comparing with GSEA on other relevant
stimulation experiments, we identified three TFs induced selec-
tively in VEGF-C156S-stimulated LECs: KLF4, SOX18, and
MAFB. Importantly, both SOX18 and KLF4 have been implicated
previously in the regulation of PROX1 (Franc¸ois et al., 2008; Park
et al., 2014), the ‘‘master’’ TF of LECs required for differentiation
andmaintenance of themature LEC phenotype (Srinivasan et al.,
2014). SOX18 is necessary for the induction of PROX1 expres-
sion in venous endothelial cells (ECs) during embryonic develop-
ment around E9.5, giving rise to a pool of progenitor cells (Fran-
c¸ois et al., 2008). KLF4, on the other hand, has been shown to be
induced transcriptionally by shear stress in endothelial cells and
to bind to a regulatory element in the PROX1 gene (Park et al.,
2014). MAFB, the third specific TF identified by our analysis,
has been implicated in the differentiation and function of various
cell types, including macrophages, kidney podocytes, and
pancreatic a and b cells (Friedman, 2007; Hamada et al., 2014;
Hang and Stein, 2011; Yang and Cvekl, 2007).
Using the full power of CAGE RNA sequencing, which not only
allows identification of differentially expressed genes but also of
the precise TSSs used, we performed a statistical analysis of
predicted transcription factor binding sites in the promoters
of upregulated genes. Although not direct proof, significant
enrichment of TF binding sites in the promoter regions of upregu-
lated genes at a given time point is a strong indication that the
corresponding TF is actively regulating gene expression. This
analysis suggested significant activity of MAFB both during the
early phase of the time course (45–60 min), concomitant with
the upregulation of the MAFB gene, and at later phases (210
and 360 min). The significant enrichment of genes with degener-
ated MAREs (MAFB_2) already after 15 min of stimulation might
result from activation of pre-existing MAFB protein in the LECs
because post-transcriptional regulation of the transcriptional
activity of MAF proteins has been described (Rocques et al.,
2007; Tillmanns et al., 2007). On the other hand, because the de-
generated MARE is less strictly defined as the MARE site, we
cannot exclude that the significant enrichment of this site at
the 15-min time point is a false positive of the analysis.
Our data suggest that MAFB, similar to SOX18 and KLF4, reg-
ulates expression of PROX1, implying that MAFB might
contribute to the maintenance of the LEC phenotype and/or to
lymphangiogenesis and that the regulation of PROX1 is medi-
ated by direct binding of MAFB to a regulatory element in the first
intron of the PROX1 gene. However, indirect regulation through
upregulation of KLF4, SOX18, and COUP-TFII cannot be
excluded, especially because the MAFB-induced upregulation
of KLF4 preceded that of PROX1. On the other hand, it is inter-
esting to note that the reported binding site of KLF4 is also
located in the first intron of PROX1 (Park et al., 2014), suggesting
that close cooperation of MAFB and KLF4 in the same cis-regu-
latory region is needed for PROX1 induction. Of note, our obser-
vation that MAFB induces expression of KLF4 is in line with a
previous report that demonstrated a similar relation between
MAFB and KLF4 during epidermal development (Lopez-Pajares
et al., 2015). We also found that MAFB expression depends on
PROX1, indicating the existence of a positive feedback loop be-
tween these two TFs. Taken together, our findings suggest that a
transcription factor network consisting of MAFB, KLF4, SOX18,
COUP-TFII, and PROX1 contributes to the establishment and
maintenance of the LEC phenotype during and/or after differen-
tiation (Figure 7D). Indeed, we found impaired patterning of
lymphatic vessels in the back skin of E14.5 embryos deficient
of MAFB. Increased vessel branching supports a role forCell RepMAFB in the fine-tuning of lymphatic development. In addition,
our data could also indicate that MAFB is involved in sensing
of VEGF-C gradients, which are believed to direct lymphatic
vessel growth during development. These findings are in line
with the very recent observation in zebrafish that mafba was
required for the migration of lymphatic precursors after their
initial sprouting from the cardinal vein (Koltowska et al., 2015).
On the other hand, the phenotype observed by us was much
less severe than the one observed for Prox1 heterozygous ani-
mals (Harvey et al., 2005; Srinivasan and Oliver, 2011), indicating
that there is a significant redundancy among the function of
MAFB and other TFs, such as KLF4, in regulating PROX1
expression.
Given the established interactions between SOX18 and
VEGF-C signaling already at initial stages of lymphangiogenesis
(Cermenati et al., 2013), MAFB deficiency may have additional
effects on the generation or budding of LEC progenitors from
the veins during earlier stages of embryonic development
(E.9.5–E13.5). Furthermore, continuous expression of MAFB in
lymphatic vessels into adulthood suggests a role in the function
and/or the maintenance of the lymphatic system in the adult
organism and, possibly, in the pathological lymphangiogenesis
associated with inflammatory and neoplastic diseases. How-
ever, global Mafb knockout in mice results in lethality within
24 hr after birth because of a defect in the PreBo¨t-C complex
in the hindbrain responsible for correct breathing (Blanchi
et al., 2003; Moriguchi et al., 2006), precluding any morpholog-
ical and functional studies in postnatal mice. Therefore, it would
be of interest to investigate the consequences of a conditional,
targeted knockout of Mafb only in lymphatic endothelial cells in
the future.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 WT mice (Charles River Laboratories) and heterozygousMafbtm1Jeng
mice on the C57BL/6 background (Moriguchi et al., 2006) (provided by Dr. Sa-
toru Takahashi, Institute of Medical Sciences, University of Tsukuba, Japan)
were bred in-house under pathogen-free conditions. For lymphatic vessel
analysis, E14.5Mafb/ andWT littermates derived from heterozygous mating
pairs were used. All animal experiments were approved by the Veterina¨ramt of
Kanton Zurich.
Cells
Primary human dermal microvascular LECs and donor-matched BECs from
foreskin (Hirakawa et al., 2003) were used. For the RNA sequencing screen,
early-passage LECs from three individual donors were starved overnight
(O/N), stimulated with VEGF-C156S (1.5 mg/ml, a gift from Prof. Kari Alitalo,
Wihuri Research Center, University of Helsinki), and lysed at 16 different
time points (0–480 min) using TRIzol (Life Technologies). For other stimulation
experiments, LECs and BECs were starved O/N and stimulated with VEGF-A
(Cell Sciences), EGF, fibroblast growth factor 2 (FGF-2) (both fromPeproTech),
and HGF (R&D Systems) at the indicated doses.
CAGE RNA Sequencing and Analysis
RNA was extracted from TRIzol lysates according to the manufacturer’s
instructions (Life Technologies). Genomic DNA was removed using g-elimi-
nator columns (QIAGEN), and RNA quality was monitored using a bioanalyzer
(Agilent). RNA samples were sequenced according to the CAGEmethod at the
RIKEN Institute (Kanamori-Katayama et al., 2011; Shiraki et al., 2003), using
the HeliScope CAGE protocol. Gene expression analysis was performed using
edgeR (Robinson et al., 2010). A list of 241 upregulated genes (encompassingorts 13, 1493–1504, November 17, 2015 ª2015 The Authors 1501
50 TFs) is provided in Table S1. GO terms enrichment analysis for the corre-
sponding genes was performed using the Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/home.
jsp). For adenovirus-infected LECs, gene expression was analyzed using
DESeq2 (Love et al., 2014). Differentially expressed genes are summarized
in Table S3. The entire gene expression data are available at http://fantom.
gsc.riken.jp/5/datafiles/phase2.0/extra (VEGF-C stimulation of LECs) and at
http://fantom.gsc.riken.jp/5/suppl/Dieterich_et_al_2015/ (MAFB overexpres-
sion in LECs).
GSEA Datasets
To identify TFs that were specifically upregulated by VEGFR-3 stimulation in
LECs, we compared our dataset with other stimulatory time courses from
the GSEA Molecular Signatures Database (http://www.broadinstitute.org/
gsea/msigdb/): VEGF-A stimulation of HUVECs (Abe and Sato, 2001), EGF
stimulation of HeLa and MCF10A cells (Amit et al., 2007), and EGF stimulation
of MCF7 cells (Nagashima et al., 2007).
oPOSSUM-3 Transcription Factor Activity Prediction
For prediction of TF activity, we used oPOSSUM-3, a tool looking for predicted
TF binding site overrepresentation in DNA sequences (Kwon et al., 2012).
Using TSSs defined by CAGE sequencing associated with refSeq transcripts,
we extracted differentially expressed refSeq transcripts using edgeR (p < 0.01)
at each time point t compared with time point t-1. Then the oPOSSUM-3 tool
was applied to core promoter sequences (1, 500 bp upstream to 500 bp down-
stream of the TSS) of each transcript using TF binding profiles from the
JASPAR database (http://www.jaspar.genereg.net) (Mathelier et al., 2014).
TF binding profiles were defined as significantly overrepresented when their
corresponding Z score or Fisher score was more than the mean + 1.5 3 SD.
siRNA Knockdown of PROX1
LECswere electroporated with two different PROX1-specific siRNAs using the
Nucleofactor II kit (Amaxa Biosystems), and RNA was extracted 48 hr later for
qPCR analysis.
In Vitro Overexpression of MAFB
For overexpression of MAFB, we used ready-made adenoviral vectors (Sirion
Biotech) with the human MAFB cDNA under control of the cytomegalovirus
(CMV) promoter (Ad-MAFB). A CMV-GFP (Ad-GFP) vector served as a control.
For transduction, LECs were infected with adenovirus at an MOI of 25. 4 hr
later, the medium was replaced, and cells were harvested at the indicated
time points.
Isolation of Primary Mouse Endothelial Cells
For isolation of primary mouse endothelial cells, back skin of C57BL/6 mice
was excised, minced, and digested with collagenase (Sigma-Aldrich). Cells
were depleted of erythrocytes using PharmLyse buffer (BD Biosciences) and
stained with primary antibodies (mouse anti-mouse CD45.2-FITC [BD Biosci-
ences], rat anti-mouse CD31-APC [BD Biosciences], and hamster anti-mouse
podoplanin [Developmental Studies Hybridoma Bank, University of Iowa]), fol-
lowed by secondary antibody (goat anti-hamster phycoerythrin [PE], Life Tech-
nologies). LECs and BECs were gated and sorted as described previously
(Halin et al., 2007).
ChIP
ChIP of LECs 72 hr after infection with Ad-MAFB or Ad-GFP was performed
essentially as described before (Nelson et al., 2006). Chromatin lysates were
incubated with rabbit anti-MAFB (Sigma-Aldrich) or corresponding control rab-
bit immunoglobulin G (IgG) (Santa Cruz Biotechnology) (mock IP), cleared by
centrifugation, and incubatedwithProteinGSepharose (GEHealthcare).Pellets
were collected by centrifugation and washed six times with IP buffer, and then
DNAwas extracted by boiling in a Chelex100 slurry (Bio-Rad). Primerswere de-
signed for selected ChIP-validated MAFF/MAFK binding sites (Wang et al.,
2013) in the genes of PROX1, KLF4, SOX18, and NR2F2AS1. qPCR was per-
formed to measure these DNA elements in specific and mock (control IgG)
IPs, with a gene without knownMAFB binding site (CCL4) serving as a negative
control. Ct values were expressed as fold change compared with mock IP.1502 Cell Reports 13, 1493–1504, November 17, 2015 ª2015 The AuTissue Whole-Mount Staining
Tissue whole mounts were fixed with paraformaldehyde (PFA), blocked in
blocking solution (5% donkey serum, 0.2% BSA, 0.3% Triton X-100, and
0.05%NaN3 in PBS), and stained with primary antibodies (in blocking solution)
O/N at 4C, followed by washing in PBS and incubation with secondary anti-
body (in PBS) for 2 hr at room temperature (RT).
Primary antibodies were as follows: rat anti-CD31 (BD Biosciences), rabbit
anti-LYVE1 (Angiobio), rabbit anti-PROX1 (Angiobio), goat anti-PROX1
(R&D), goat anti-NRP2 (R&D), goat anti-CD206 (R&D), rat anti-CD68 (Abcam),
and rabbit anti-MAFB (Sigma-Aldrich). Secondary antibodies were as follows:
donkey anti-goat Al488, donkey anti-rat Al488, donkey anti-rabbit Al594,
donkey anti-goat Al594, and donkey anti-rabbit Al647 (all from Life Technolo-
gies). Confocal images (z stacks) were taken with an LSM710 or LSM780 mi-
croscope (Zeiss), andmaximum intensity projections, 3D reconstructions, and
image analysis were made with ImageJ.
Statistics
All graphs and statistical tests were done using GraphPad Prism. If not stated
differently, error bars represent mean values + SD. Student’s t test was used to
detect significant differences (p < 0.05).
More detailed methods can be found in the Supplemental Experimental
Procedures.
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